Literature DB >> 20498310

Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.

Soo-Jin Yang1, Cynthia C Nast, Nagendra N Mishra, Michael R Yeaman, Paul D Fey, Arnold S Bayer.   

Abstract

The mechanism(s) of daptomycin (DAP) resistance (DAPr) is incompletely defined. Thickened cell walls (CWs) acting as either a mechanical barrier or an affinity trap for DAP have been purported to be a major contributor to the DAPr phenotype. To this end, we studied an isogenic set of methicillin-resistant Staphylococcus aureus (MRSA) isolates (pulsotype USA 300) from the bloodstream of a DAP-treated patient with endocarditis in which serial strains exhibited increasing DAPr. Of interest, the DAPr isolate differed from its parental strain in several parameters, including acquisition of a point mutation within the putative synthase domain of the mprF gene in association with enhanced mprF expression, increased synthesis of lysyl-phosphotidylglycerol, an enhanced positive envelope charge, and reduced DAP surface binding. Transmission electron microscopy (TEM) revealed no significant increases in CW thickness in the two DAPr isolates (MRSA 11/21 and REF2145) compared with that in the DAP-susceptible (DAPs) parental strain, MRSA 11/11. The rates of Triton X-100-induced autolysis were also identical for the strain set. Furthermore, among six additional clinically isolated DAPs/DAPr S. aureus strain pairs, only three DAPr isolates exhibited CWs significantly thicker than those of the respective DAPs parent. These data confirm that CW thickening is neither universal to DAPr S. aureus nor sufficient to yield the DAPr phenotype among S. aureus strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498310      PMCID: PMC2916340          DOI: 10.1128/AAC.00122-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.

Authors:  Paul G Mariani; Helio S Sader; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2006-08       Impact factor: 5.790

2.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Authors:  Satish K Pillai; Howard S Gold; George Sakoulas; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

4.  Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.

Authors:  Ilana Lopes Baratella da Cunha Camargo; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

5.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

6.  Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.

Authors:  Soo-Jin Yang; Yan Q Xiong; Paul M Dunman; Jacques Schrenzel; Patrice François; Andreas Peschel; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

7.  Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate.

Authors:  Madhukiran H Murthy; Michael E Olson; Robert W Wickert; Paul D Fey; Ziba Jalali
Journal:  J Med Microbiol       Date:  2008-08       Impact factor: 2.472

8.  Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.

Authors:  Tahaniyat Lalani; Jerome J Federspiel; Helen W Boucher; Thomas H Rude; In-Gyu Bae; Michael J Rybak; Giang T Tonthat; G Ralph Corey; Martin E Stryjewski; George Sakoulas; Vivian H Chu; Jeff Alder; Judith N Steenbergen; Steven A Luperchio; Marilyn Campion; Christopher W Woods; Vance G Fowler
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

Review 9.  Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.

Authors:  Helen W Boucher; George Sakoulas
Journal:  Clin Infect Dis       Date:  2007-08-01       Impact factor: 9.079

10.  Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.

Authors:  Nagendra N Mishra; Soo-Jin Yang; Ayumi Sawa; Aileen Rubio; Cynthia C Nast; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

View more
  59 in total

1.  Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors:  Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

Review 2.  Roles of tRNA in cell wall biosynthesis.

Authors:  Kiley Dare; Michael Ibba
Journal:  Wiley Interdiscip Rev RNA       Date:  2012-01-19       Impact factor: 9.957

3.  Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?

Authors:  Truc T Tran; Siraya Jaijakul; Cole T Lewis; Lorena Diaz; Diana Panesso; Heidi B Kaplan; Barbara E Murray; Audrey Wanger; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

4.  Impact of daptomycin resistance on Staphylococcus aureus virulence.

Authors:  David R Cameron; Lawrence I Mortin; Aileen Rubio; Eleftherios Mylonakis; Robert C Moellering; George M Eliopoulos; Anton Y Peleg
Journal:  Virulence       Date:  2015       Impact factor: 5.882

5.  In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  Nagendra N Mishra; James McKinnell; Michael R Yeaman; Aileen Rubio; Cynthia C Nast; Liang Chen; Barry N Kreiswirth; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Authors:  Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

7.  Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis.

Authors:  Anna-Barbara Hachmann; Elif Sevim; Ahmed Gaballa; David L Popham; Haike Antelmann; John D Helmann
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus.

Authors:  Nagendra N Mishra; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.